Premarket Movers | CORT Surges 26% as Q2 Earnings Easily Beat Expectations and Full-Year Guidance Is Raised

Market Focus07-30

On July 30, Corcept Therapeutics rose over 26% in pre-market trading. The surge was driven by the company's Q2 earnings release, which dramatically exceeded market expectations. Corcept reported EPS of $0.36, far surpassing the analyst consensus estimate of $0.02, representing a 24.14% year-over-year increase. Revenue reached $256.1 million, up from $194.4 million a year earlier, beating estimates of approximately $221 million by roughly 16%.

The outperformance was primarily attributed to the commercial progress of core product Korlym and newly approved drug Lifyorli. Additionally, the company raised full-year revenue guidance to $1.1 billion-$1.2 billion, significantly above its prior forecast of $950 million-$1.05 billion and the FactSet consensus of $999.5 million. The company also resubmitted its New Drug Application for Relacorilant for Cushing's syndrome treatment in June. Canaccord Genuity raised its price target from $135 to $150, further boosting market confidence.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

4

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1148254432?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-30 16:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1148254432","market":"us","top_or_hot":-1,"title":"Premarket Movers | CORT Surges 26% as Q2 Earnings Easily Beat Expectations and Full-Year Guidance Is Raised","media":"Market Focus","content":"<html><head></head><body><p style=\"text-align: left;\">On July 30, Corcept Therapeutics rose over 26% in pre-market trading. The surge was driven by the company&#39;s Q2 earnings release, which dramatically exceeded market expectations. Corcept reported EPS of $0.36, far surpassing the analyst consensus estimate of $0.02, representing a 24.14% year-over-year increase. Revenue reached $256.1 million, up from $194.4 million a year earlier, beating estimates of approximately $221 million by roughly 16%.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/30cd64d19b481ea7b5bf46bdf7c82dfa\" data-align=\"center\" tg-width=\"540\" tg-height=\"159\"/><span></span></p><p style=\"text-align: left;\">The outperformance was primarily attributed to the commercial progress of core product Korlym and newly approved drug Lifyorli. Additionally, the company raised full-year revenue guidance to $1.1 billion-$1.2 billion, significantly above its prior forecast of $950 million-$1.05 billion and the FactSet consensus of $999.5 million. The company also resubmitted its New Drug Application for Relacorilant for Cushing&#39;s syndrome treatment in June. Canaccord Genuity raised its price target from $135 to $150, further boosting market confidence.</p><p style=\"text-align: left;\">(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p><p style=\"text-align: left;\"></p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Premarket Movers | CORT Surges 26% as Q2 Earnings Easily Beat Expectations and Full-Year Guidance Is Raised</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPremarket Movers | CORT Surges 26% as Q2 Earnings Easily Beat Expectations and Full-Year Guidance Is Raised\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-30 16:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p style=\"text-align: left;\">On July 30, Corcept Therapeutics rose over 26% in pre-market trading. The surge was driven by the company&#39;s Q2 earnings release, which dramatically exceeded market expectations. Corcept reported EPS of $0.36, far surpassing the analyst consensus estimate of $0.02, representing a 24.14% year-over-year increase. Revenue reached $256.1 million, up from $194.4 million a year earlier, beating estimates of approximately $221 million by roughly 16%.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/30cd64d19b481ea7b5bf46bdf7c82dfa\" data-align=\"center\" tg-width=\"540\" tg-height=\"159\"/><span></span></p><p style=\"text-align: left;\">The outperformance was primarily attributed to the commercial progress of core product Korlym and newly approved drug Lifyorli. Additionally, the company raised full-year revenue guidance to $1.1 billion-$1.2 billion, significantly above its prior forecast of $950 million-$1.05 billion and the FactSet consensus of $999.5 million. The company also resubmitted its New Drug Application for Relacorilant for Cushing&#39;s syndrome treatment in June. Canaccord Genuity raised its price target from $135 to $150, further boosting market confidence.</p><p style=\"text-align: left;\">(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p><p style=\"text-align: left;\"></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CORT","symbol_name":"Corcept医疗","start_time":0,"source_url":"","article_id":"1148254432","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1148254432","pubTimestamp":1785398708,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 30, Corcept Therapeutics rose 20.48% in pre-market trading, trading at $111.11/share, with turnover of $80,100.The surge was driven by the company's Q2 earnings release, which dramatically...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CORT":"Corcept医疗"},"translate_title":"盘前推动者 | 第二季度盈利轻松超出预期并上调全年指引，CORT 股价飙升 26%","themeId":null,"isJumpTheme":false,"ttsUrl":"https://static.tigerbbs.com/d9cf540821b6181e94f79f8b4f7b8899","symbols_score_info":{"CORT":1},"content_text":"On July 30, Corcept Therapeutics rose over 26% in pre-market trading. The surge was driven by the company's Q2 earnings release, which dramatically exceeded market expectations. Corcept reported EPS of $0.36, far surpassing the analyst consensus estimate of $0.02, representing a 24.14% year-over-year increase. Revenue reached $256.1 million, up from $194.4 million a year earlier, beating estimates of approximately $221 million by roughly 16%.The outperformance was primarily attributed to the commercial progress of core product Korlym and newly approved drug Lifyorli. Additionally, the company raised full-year revenue guidance to $1.1 billion-$1.2 billion, significantly above its prior forecast of $950 million-$1.05 billion and the FactSet consensus of $999.5 million. The company also resubmitted its New Drug Application for Relacorilant for Cushing's syndrome treatment in June. Canaccord Genuity raised its price target from $135 to $150, further boosting market confidence.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":4,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1148254432","isCrawlerRequest":true}